Floatz logo

Nivolumab

Stage IIB Anal Cancer AJCC v8

National Cancer Institute (NCI)monoclonal_antibodyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Stage IIB Anal Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Retifanlimab
Incyte Corporation
Phase 3BB
Carboplatin
Incyte Corporation
Phase 3BB
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
M.D. Anderson Cancer Center
Phase 2B
MITOMYCIN C
National Cancer Institute (NCI)
Phase 2CCC

View all 11 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →